Combinations of pembrolizumab and targeted therapies for advanced clear cell kidney cancer
The KEYMAKER-U03 study is looking at different combinations of immunotherapy [...]
Promising new combination therapy for advanced kidney cancer
Combinations of tyrosine kinase inhibitors plus immunotherapy have improved treatment [...]
FDA approves injectable form of nivolumab
Just after Christmas, the US Food and Drug Administration (FDA) [...]
Promising new immunotherapy combination for advanced kidney cancer
The first results from a phase 2 study (FRACTION-RCC) looking [...]
Multi-million-pound UK-wide research into cancer immunotherapy
The Francis Crick Institute and The Royal Marsden NHS Foundation [...]
Pazopanib plus bevacizumab shows promise as a first-line treatment for kidney cancer
Results from a phase 2 study of pazopanib alternated with [...]
Intermittent immunotherapy in patients with metastatic kidney cancer
The combination of ipilimumab/nivolumab is approved for patients as a [...]
Patient perspectives on immunotherapy dosing schedules
Immunotherapy (in particular immune checkpoint inhibitors) has transformed the treatment [...]
Stereotactic radiotherapy plus immunotherapy for brain metastases
Stereotactic radiosurgery (SRS) is a procedure that uses special equipment [...]
Treatment options in first-line metastatic kidney cancer
Over the past 10 years or so, the use of [...]
